MedReLeaf Corporation has been granted an amended licence from Health Canada to allow sales of medical cannabis under the Access to Cannabis for Medical Purposes Regulations (ACMPR) at its second location in Bradford, Ontario. This will increase the current licenced production and sales capacity by 80 per cent to an approximate 12,600 kg per year.
“Just six months after receiving our cultivation licence at Bradford, we are among the fastest producers to receive a sales licence and have completed multiple harvests at best-in-class cultivation yields of 300 grams per square foot,” said Neil Closner, CEO of MedReleaf. “As our industry grows, our proven ability to execute large-scale projects while maintaining the highest quality standards further solidifies MedReleaf as a trusted leader amongst licensed producers.”
This latest amended license from Health Canada follows several other recent amendments at the Bradford facility. On October 11, 2017, MedReleaf received its amended licence for the use of its Mother Room and Clone Room which will support the growing capacity at the Bradford facility. On October 20, 2017, the company received another amended licence for the use of two additional cultivation rooms, effectively doubling annual production capacity to an estimated 5,600 kg at the Bradford facility. Completion of the facility in Bradford is scheduled for the summer of 2018. Compiling both the Markham and the Bradford facilities, MedReLeaf will have a total licensed production and sales capacity expectation of 35,000 kg per year.
MedReLeaf is the first and only company in North America to be an ISO 9001 certified cannabis producer. The company has many assorted products for medicinal marijuana that will come with the option of a lockable box to keep it fresh and stored where children and other wandering hands are unable to reach.
Cannabis has been used by humans for thousands of years for a variety of reasons. It is only now, with the softening of legal laws that companies like MedReLeaf can produce and sell the substance legally and researchers can further investigate the healing properties of the cannabinoid plant.